Ifetroban is under clinical development by Cumberland Pharmaceuticals and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ifetroban’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ifetroban overview

Ifetroban (Vasculan, Boxaban, Hepatoren,Portaban) is under development for the treatment of hepatorenal syndrome (HRS), portal hypertension, systemic sclerosis, duchenne muscular dystrophy and aspirin exacerbated respiratory disease (AERD), a respiratory disease involving chronic asthma and nasal polyps. It is also under development for the treatment of metastatic solid tumors including triple negative breast cancer, pancreatic cancer, lung cancer, esophageal cancers, stomach cancer, idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases. The drug candidate is administered through oral route and as infusion through intravenous route. Ifetroban acts by targeting thromboxane A2/prostaglandin H2 receptor.

It was under development for the treatment of pacing-induced ischemia, squamous cell carcinoma (SCCA).

Cumberland Pharmaceuticals overview

Cumberland Pharmaceuticals (Cumberland), is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription products. Its primary target markets are hospital acute care, gastroenterology, and cancer supportive care. The company offers branded prescription products under Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Ethyol, Totect, Hepatoren, Boxaban, Vasculan, Portaban, and RediTrex brand names. Cumberland Pharma promotes approved products through its hospital and gastroenterology sales forces in the US. The company is also establishing a network of international partners to commercialize its products in their countries. Cumberland Pharma is headquartered in Nashville, Tennessee, the US.

For a complete picture of Ifetroban’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.